Format

Send to

Choose Destination
Asian J Psychiatr. 2015 Dec;18:111-2. doi: 10.1016/j.ajp.2015.09.004. Epub 2015 Sep 21.

Ramelteon-induced nightmares: A case report.

Author information

1
Department of Psychiatry & Behavioral Medicine, Carilion Clinic-Virginia Tech Carilion, First Floor Administrative Suites, 2017 South Jefferson Street, Roanoke 24014, VA, United States. Electronic address: shahc@upmc.edu.
2
Department of Psychiatry & Behavioral Medicine, Carilion Clinic-Virginia Tech Carilion, First Floor Administrative Suites, 2017 South Jefferson Street, Roanoke 24014, VA, United States.

Abstract

Ramelteon is the only FDA-approved melatonin agonist for treatment of insomnia. It acts on melatonin MT1 and MT2 receptors. We describe a case of a patient who was prescribed ramelteon for insomnia disorder. Shortly after initiation of ramelteon, he described vivid nightmares leading to discontinuation of ramelteon. The nightmares ameliorated with ramelteon discontinuation. Ramelteon is well tolerated with a favorable side-effect profile. No documented cases of nightmares secondary to ramelteon use were found in the literature. The effects of ramelteon on rapid eye movement sleep, the stage of sleep where dreams occur, need to be further explored.

KEYWORDS:

Dreams; Nightmares; Ramelteon

PMID:
26427581
DOI:
10.1016/j.ajp.2015.09.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center